ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia

Zhao, Ze An; Jiang, Yu; Chen, Yan-yu; Wu, Ting; Lan, Qun-sheng; Li, Yong-mei; Li, Lu; Yang, Yang; Lin, Cui-ting; Cao, Ying; Zhou, Ping-zheng; Guo, Jia-yin*; Tian, Yuan-xin*; Pang, Jian-xin*南方医科大学
Acta Pharmacologica Sinica2022-1DOI: 10.1038/s41401-021-00640-5
15被引12阅读
引用收藏
分享

摘要

Urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) are important targets for the development of uric acid-lowering drugs. We previously showed that the flexible linkers of URAT1 inhibitors could enhance their potency. In this study we designed and synthesized CDER167, a novel RDEA3710 analogue, by introducing a linker (methylene) between the naphthalene and pyridine rings to increase flexibility, and characterized its pharmacological and pharmacokinetics properties in vitro and in vivo. We showed that CDER167 exerted dual-target inhibitory effects on both URAT1 and GLUT9: CDER167 concentration-dependently inhibited the uptake of [C-14]-uric acid in URAT1-expressing HEK293 cells with an IC50 value of 2.08 +/- 0.31 mu M, which was similar to that of RDEA3170 (its IC50 value was 1.47 +/- 0.23 mu M). Using site-directed mutagenesis, we demonstrated that CDER167 might interact with URAT1 at S35 and F365. In GLUT9-expressing HEK293T cells, CDER167 concentration-dependently inhibited GLUT9 with an IC50 value of 91.55 +/- 15.28 mu M, whereas RDEA3170 at 100 mu M had no effect on GLUT9. In potassium oxonate-induced hyperuricemic mice, oral administration of CDER167 (10 mg.kg(-1).d(-1)) for 7 days was more effective in lowering uric acid in blood and significantly promoted uric acid excretion in urine as compared with RDEA3170 (20 mg.kg(-1).d(-1)) administered. The animal experiment proved the safety of CDER167. In addition, CDER167 displayed better bioavailability than RDEA3170, better metabolic stability and no hERG toxicity at 100 mu M. These results suggest that CDER167 deserves further investigation as a candidate antihyperuricemic drug targeting URAT1 and GLUT9.

学科与关键词

关键词
gouthyperuricemiauric acid-lowering drugsRDEA3710CDER167urate transporter 1 (URAT1)glucose transporter 9 (GLUT9)
相关
加载中…
  • CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia (vol 43, pg 121, 2022)
    Zhao, Ze-an; Jiang, Yu; Chen, Yan-yu; Wu, Ting; Lan, Qun-sheng; Li, Yong-mei; Li, Lu; Yang, Yang; Lin, Cui-ting; Cao, Ying; Zhou, Ping-zheng; Guo, Jia-yin*; Tian, Yuan-xin*; Pang, Jian-xin*Acta Pharmacologica Sinica, 2022, 43(7): 1884-1884.
  • Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia
    Zhao, Zean; Liu, Jin; Kuang, Peihua; Luo, Jian; Surineni, Goverdhan; Cen, Xiaolin; Wu, Ting; Cao, Ying; Zhou, Pingzheng; Pang, Jianxin*; Zhang, Qun*; Chen, Jianjun*European Journal of Medicinal Chemistry, 2022, 229: 114092.被引 9
  • Pharmacological evaluation of a novel skeleton compound isobavachin (4?,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity
    Zhao, Zean; Luo, Jian; Liao, Hui; Zheng, Fengxin; Chen, Xinhua; Luo, Jiajun; Chen, Yongjun; Zhao, Kunlu; Zhang, Shuqin; Tian, Jinhong; Wu, Ting; Li, Yongmei; Li, Lu; Yang, Yang; Lin, Cuiting; Zhang, Qun*; Tian, Yuanxin*; Pang, Jianxin*Bioorganic Chemistry, 2023, 133: 106405.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Acta Pharmacologica Sinica
发表日期
2022-01
卷期
第 43 卷, 第 1 期
页码
121-132
DOI
10.1038/s41401-021-00640-5
语言
ENGLISH
期刊收录
CSCD-C.CAST-P
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773794, 81974507]; Natural Science Foundation of Guangdong Province [2018A0303130088]

作者

  • Z

    Zhao, Ze An (第一作者)

    southern med univ

  • J

    Jiang, Yu

    southern med univ

查看全部 14 位作者收起作者
  • C

    Chen, Yan-yu

    southern med univ

  • W

    Wu, Ting

    southern med univ

  • L

    Lan, Qun-sheng

    southern med univ

  • L

    Li, Yong-mei

    southern med univ

  • L

    Li, Lu

    southern med univ

  • Y

    Yang, Yang

    southern med univ

  • L

    Lin, Cui-ting

    southern med univ

  • C

    Cao, Ying

    southern med univ

  • Z

    Zhou, Ping-zheng

    southern med univ

  • G

    Guo, Jia-yin (通讯)

    southern med univ

  • T

    Tian, Yuan-xin (通讯)

    southern med univ

  • P

    Pang, Jian-xin (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417